Dexpramipexole dihydrochloride

Synonyms: 右旋普拉克索二盐酸盐; (R)-Pramipexole dihydrochloride; R-(+)-Pramipexole dihydrochloride; KNS-760704 dihydrochloride
Dexpramipexole ((R)-Pramipexole) dihydrochloride 是一种口服有效且可透过血脑屏障的线粒体保护剂,可上调 Parkin、PINK1、GPX4 和 FSP1 的表达,结合线粒体 F1/Fo-ATP 合酶,阻断 Nav1.8 钠离子通道,并抑制 NLRP3 炎症小体的激活,同时可诱导线粒体自噬 (mitophagy),抑制铁死亡 (ferroptosis)、细胞焦亡 (pyroptosis)、细胞凋亡 (apoptosis)、神经炎症及嗜酸性粒细胞生成,维持线粒体功能与氧化还原稳态,减少活性氧 (ROS) 生成,并缩小心肌梗死面积,因此可用于嗜酸性粒细胞性哮喘、心肌缺血/再灌注损伤、脓毒症相关脑病、镇痛等研究。
产品编号: MS-K16180 纯度: 99.94% CAS No.: 104632-27-1 分子式: C10H19Cl2N3S 分子量: 284.25
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Dexpramipexole ((R)-Pramipexole) dihydrochloride 是一种口服有效且可透过血脑屏障的线粒体保护剂,可上调 Parkin、PINK1、GPX4 和 FSP1 的表达,结合线粒体 F1/Fo-ATP 合酶,阻断 Nav1.8 钠离子通道,并抑制 NLRP3 炎症小体的激活,同时可诱导线粒体自噬 (mitophagy),抑制铁死亡 (ferroptosis)、细胞焦亡 (pyroptosis)、细胞凋亡 (apoptosis)、神经炎症及嗜酸性粒细胞生成,维持线粒体功能与氧化还原稳态,减少活性氧 (ROS) 生成,并缩小心肌梗死面积,因此可用于嗜酸性粒细胞性哮喘、心肌缺血/再灌注损伤、脓毒症相关脑病、镇痛等研究。

生物实验数据

生物活性 Dexpramipexole ((R)-Pramipexole) dihydrochloride is an orally active, blood-brain barrier-permeable mitochondrial protectant that upregulates the expression of Parkin, PINK1, GPX4, and FSP1, binds to mitochondrial F1/Fo-ATP synthase, blocks Nav1.8 sodium channels, and inhibits NLRP3 inflammasome activation, while also inducing mitophagy, inhibiting ferroptosis, pyroptosis, apoptosis, neuroinflammation, and eosinophilopoiesis, maintaining mitochondrial function and redox homeostasis, reducing reactive oxygen species (ROS) production, and reducing myocardial infarct size, and can therefore be used for research on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and other conditions.
体外研究
(In Vitro)

Dexpramipexole (5-200 μM; 24 h) dihydrochloride 在 100 μM 以下浓度时,对新生大鼠原代心肌细胞无细胞毒性,而 200 μM 的该化合物会降低细胞活力。
Dexpramipexole (2-50 μM) dihydrochloride 通过提高细胞活力并降低 LDH 释放,保护原代新生大鼠心肌细胞免受缺氧 / 复氧 (H/R) 诱导的损伤。
Dexpramipexole (2-50 μM) dihydrochloride 可上调受到 H/R 作用的新生大鼠原代心肌细胞中 PINK1 蛋白的表达水平。
Dexpramipexole dihydrochloride 通过减少 mPTP 开放、降低 ROS 生成及恢复线粒体膜电位,保护新生大鼠原代心肌细胞免受 H/R 诱导的线粒体功能损伤。
Dexpramipexole dihydrochloride 可增强受 H/R 作用的新生大鼠原代心肌细胞中依赖 ATG7 的线粒体自噬,表现为线粒体自噬体形成增加、自噬性线粒体隔离及线粒体清除增强。
Dexpramipexole dihydrochloride 可在暴露于 H/R 的新生大鼠原代心肌细胞中激活 PINK1 和 Parkin,并促进线粒体分裂。
Dexpramipexole dihydrochloride 可通过上调 PINK1 和 Parkin 依赖的线粒体自噬,保护新生大鼠原代心肌细胞免受 H/R 损伤。
Dexpramipexole (10 μM; 5 min) dihydrochloride 可抑制原代培养大鼠背根神经节神经元中河豚毒素不敏感型钠电流,其 IC50 为 294.4 nM,且不会改变通道的电压依赖性激活或失活特性。
Dexpramipexole (10 μM) dihydrochloride 选择性的抑制原代培养的野生型小鼠背根神经节神经元中由 Nav1.8 介导的钠电流。

体内研究
(In Vivo)

Dexpramipexole (1 mg/kg; 单次给药) dihydrochloride 可通过缩小梗死面积、恢复心脏功能、降低血清心肌损伤生物标志物水平以及增强 PINK1/Parkin 依赖性线粒体自噬,减轻雄性 C57BL/6 小鼠的心肌缺血/再灌注损伤。
Dexpramipexole (5-20 mg/kg; i.p., 每日一次共 14 天) dihydrochloride 可改善脑出血小鼠的生存率、体重增长、自主活动能力、运动协调性及前肢肌力,缩小血肿体积,减轻白质损伤,减少铁和 ROS 蓄积,并通过上调 GPX4 和 FSP1 抑制铁死亡。
Dexpramipexole (3 mg/kg; i.p.; 每日一次共 6 天) dihydrochloride 可改善脂多糖 (LPS) 诱导的 SAE 认知障碍,保护小鼠海马线粒体的形态与功能,并抑制线粒体介导的细胞焦亡和细胞凋亡。
Dexpramipexole (3-20 mg/kg; 20-140 μg/20 μL; p.o.; i.p.; 后爪 s.c.; 单次给药) dihydrochloride 在小鼠的多种伤害性疼痛 (如炎症痛、内脏痛) 和神经性疼痛 (如化疗诱导痛、神经压迫痛、糖尿病神经痛) 模型中均能产生有效的镇痛作用。

Animal Model: C57BL/6 (male, 9-10 weeks old, 24-26 g; intracerebral hemorrhage induced by stereotactic injection of autologous tail vein blood)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: i.p., once daily for 14 days
Result: Significantly increased the survival rate of mice after cerebral hemorrhage.
Slowed down the postoperative weight loss and promoted the recovery of motor function, motor coordination ability, muscle strength and comprehensive neurological function (BMS).
Reduced iron deposition around the hematoma and the accumulation of reactive oxygen species.
Increased the expression of GPX4 and FSP1.
Animal Model: C57BL/6 (male, 3 months old, 20-28 g, LPS-induced sepsis-associated encephalopathy)
Dosage: 3 mg/kg
Administration: i.p., once daily for 6 days
Result: Improved the long-term cognitive dysfunction caused by LPS, particularly spatial working memory and hippocampus-dependent memory.
Protected the mitochondria of hippocampal neurons, improved their morphology (reduced swelling) and function (maintained ATP levels, reduced ROS).
Inhibited pyroptosis and apoptosis of cells
Animal Model: CD-1 (male, 20-25 g, intraplantar formalin injection-induced inflammatory pain)
Dosage: 3 mg/kg; 10 mg/kg; 20 μg/20 μL; 70 μg/20 μL; 140 μg/20 μL
Administration: p.o.; single dose 1 h before test; i.p.; single dose 1 h before test; s.c. in hind paw; single dose 10 min before test
Result: Reduced time spent in pain-like behaviors during the early formalin phase (10 mg/kg p.o.).
Reduced time spent in pain-like behaviors dose-dependently during the late formalin phase (3 mg/kg, 10 mg/kg p.o.).
Reduced time spent in pain-like behaviors dose-dependently during the late formalin phase (3 mg/kg, 10 mg/kg i.p.).
Reduced time spent in pain-like behaviors during the late formalin phase (70 μg/20 μL, 140 μg/20 μL s.c.).
Caused no effect on pain-like behaviors in the early phase at any tested subdermal dose.
Animal Model: CD-1 (male, 20-25 g; female, intraperitoneal acetic acid injection-induced visceral pain)
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.p.; single dose 1 h before test
Result: Reduced the number of abdominal writhings dose-dependently in male mice
. Reduced the number of abdominal writhings in female mice.
Animal Model: CD-1 (male, 20-25 g, ankle complete Freund adjuvant injection-induced chronic inflammatory arthritis pain)
Dosage: 70 μg/20 μL
Administration: s.c. in hind paw; single dose 10 min before each test on day 7, 14, 21
Result: Increased mechanical thresholds at day 7, 14, and 21 post CFA injection.
Animal Model: CD-1 (subcutaneous oxaliplatin injection-induced acute chemotherapy-induced neuropathic pain)
Dosage: 10 mg/kg; 70 μg/20 μL
Administration: i.p.; single dose 30 min post oxaliplatin; s.c. in hind paw; single dose 50 min post oxaliplatin
Result: Reduced cold pain-related behaviors at 1, 2, 3, 4, and 5 h post oxaliplatin injection (10 mg/kg i.p.).
Reduced cold pain-related behaviors at 1 hour post oxaliplatin injection (70 μg/20 μL, s.c.).
Animal Model: CD-1 (intraperitoneal oxaliplatin injection-induced chronic chemotherapy-induced neuropathic pain)
Dosage: 10 mg/kg
Administration: i.p.; single dose 1 h before test; p.o.; single dose 1 h before test
Result: Reduced cold allodynia at day 21 post initial oxaliplatin injection (10 mg/kg i.p.).
Reduced cold allodynia at 1, 3, and 6 hours post dosing, with effects diminishing by 9 hours (10 mg/kg p.o.).
Animal Model: CD-1 (male, 20-25 g, chronic constriction injury of right sciatic nerve-induced neuropathic pain)
Dosage: 10 mg/kg
Administration: i.p.; single dose 1 h before test
Result: Reduced mechanical allodynia in the injured hind paw.
Animal Model: CD-1 (intraperitoneal streptozotocin injection-induced diabetic neuropathic pain, blood glucose > 250 mg/dl confirmed 3 weeks post-injection)
Dosage: 10 mg/kg
Administration: i.p.; single dose 1 h before test
Result: Increased latency to pain-related behaviors in diabetic mice.
性状 固体
颜色 White to off-white

化学信息

分子量 284.25
分子式 C10H19Cl2N3S
CAS No. 104632-27-1
别名 右旋普拉克索二盐酸盐; (R)-Pramipexole dihydrochloride; R-(+)-Pramipexole dihydrochloride; KNS-760704 dihydrochloride

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 2.08 mg/mL (7.32 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (14.07 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 100 mg/mL (351.79 mM; 超声助溶)

DMSO 中的溶解度 : ≥ 100 mg/mL (351.79 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / DMSO1 mM3.5179 mL17.5895 mL35.1791 mL87.9477 mL
5 mM0.7036 mL3.5179 mL7.0358 mL17.5895 mL
10 mM0.3518 mL1.7590 mL3.5179 mL8.7948 mL
15 mM0.2345 mL1.1726 mL2.3453 mL5.8632 mL
20 mM0.1759 mL0.8795 mL1.7590 mL4.3974 mL
25 mM0.1407 mL0.7036 mL1.4072 mL3.5179 mL
30 mM0.1173 mL0.5863 mL1.1726 mL2.9316 mL
40 mM0.0879 mL0.4397 mL0.8795 mL2.1987 mL
50 mM0.0704 mL0.3518 mL0.7036 mL1.7590 mL
60 mM0.0586 mL0.2932 mL0.5863 mL1.4658 mL
80 mM0.0440 mL0.2199 mL0.4397 mL1.0993 mL
100 mM0.0352 mL0.1759 mL0.3518 mL0.8795 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础